Royalty Pharma reported a 6% increase in Portfolio Receipts to $773 million in Q2 2026, driven by a 14% rise in Royalty Receipts from key drugs like Tremfya and Evrysdi. The company acquired new royalty interests, including AstraZeneca’s cliramitug, expanding its development pipeline to 19 therapies. Strong financial results led Royalty Pharma to raise its full-year 2026 Portfolio Receipts guidance to $3.4-$3.5 billion, reflecting continued growth and robust capital deployment exceeding $1 billion. This positions Royalty Pharma well for sustained growth in the biopharmaceutical royalty market.
Pomerantz LLP is investigating AstraZeneca and some of its executives for potential securities fraud following the failure of the Phase-3 CARDIO-TTransform trial for Wainua, a treatment for amyloid cardiomyopathy. The trial did not meet its primary e...
SOPHiA GENETICS announced a multi-year collaboration with AstraZeneca to develop and commercialize two companion diagnostics supporting precision oncology therapies. The partnership will focus on creating decentralized diagnostics for solid tumors an...
The FTSE 100 fell 30 points to 10,838, dragged down by AstraZeneca's 9.3% drop following reports of merger talks with Bristol Myers Squibb, which raised concerns over strategic fit and antitrust issues. Commodity giants like Rio Tinto and BP also dec...
AIM ImmunoTech announced that the final patient has received their last dose in the Phase 2 DURIPANC trial testing Ampligen combined with AstraZeneca's Imfinzi for metastatic pancreatic cancer, ahead of schedule. The primary endpoint analysis will st...
Wall Street is expected to start August mostly higher with Dow Jones futures up 1% and S&P 500 gaining 0.5%, while Nasdaq futures remain flat following a recent tech rebound. Last month, technology stocks struggled, notably the Philadelphia Semicondu...
